Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 10, 2020

SELL
$14.08 - $18.5 $237,262 - $311,743
-16,851 Closed
0 $0
Q2 2019

Aug 07, 2019

SELL
$12.93 - $16.83 $191,286 - $248,983
-14,794 Reduced 46.75%
16,851 $247,000
Q1 2019

May 13, 2019

BUY
$11.09 - $15.83 $350,943 - $500,940
31,645 New
31,645 $468,000

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.03B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Granite Investment Partners, LLC Portfolio

Follow Granite Investment Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Granite Investment Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Granite Investment Partners, LLC with notifications on news.